TORONTO and HAIFA, Israel, Nov. 28, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV:NRX) (OTCQB:NRXBF) (FSE: J90) (“NurExone” or the “Company“), a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system injuries, is pleased to announce its financial results for the third quarter ended September 30, 2025 (“Q3 2025“) and provided a corporate update on recent achievements and upcoming milestones.
The Company’s unaudited condensed interim consolidated financial statements for the nine months ended September 30, 2025, and accompanying management’s discussion and analysis, can be accessed by visiting the Company’s website at www.nurexone.com and its SEDAR+ profile at www.sedarplus.ca.
Recent Corporate Highlights and Business Updates Following Q3 2025
Acceleration and Full Exercise of 2023 and 2024 Warrants
On October 8, 2025, the Company accelerated the expiry of 8.2 million warrants issued in 2023 and 2024 after meeting the prescribed acceleration thresholds. All warrants were exercised before the accelerated expiry date, November 7, 2025, resulting in total gross proceeds of approximately C$3.2 million, which will support general corporate and working capital needs as further discussed in the Company’s press release, dated November 12, 2025.
Reproducible Dose-Dependent Vision Recovery in Glaucoma Model
Also on October 8, 2025, NurExone announced new preclinical data demonstrating consistent, dose-dependent vision recovery in its glaucoma and optic nerve injury model. Repeated studies showed that higher doses of ExoPTEN reliably restored retinal function to near-baseline STR-ERG levels and significantly improved retinal ganglion cell survival compared to controls. The reproducibility of these results further reinforces the biological rationale for ExoPTEN as a therapy for optic nerve regeneration.
Strengthening Global Scientific Leadership in Therapeutic Exosomes
NurExone enhanced its global scientific visibility through invited presentations at leading exosome and regenerative-medicine meetings, including the Precision EV Forum 2025 in Cambridge, U.K. Moreover, Dr. Lior Shaltiel has been invited to speak and serve as a panelist at the upcoming Cell and Gene Therapy International Europe conference in Berlin in December.
Recognition in Prestigious Global Award Competitions
On November 12, 2025, the Company announced it was named a finalist in two respected international programs: the Falling Walls Science Breakthroughs (Berlin, November 2025) and the Prix Galien Bridges Awards (Stockholm, December 2025). These recognitions highlight the innovative nature of the Company’s regenerative-medicine approach.
Upcoming Investor Webinar: “Investing in the Future of Exosome Therapeutics”
NurExone will host an investor webinar on December 10, 2025, at 10:00 AM EST to discuss recent achievements, U.S. biomanufacturing expansion, and strategic priorities for 2026. Register here.
Key Business Highlights
C$1.4 Million Raised Through Private Placements
On August 20, 2025, the Company completed a non-brokered private placement of 1,258,072 units (each, an “August 2025 Unit“) at a price of C$0.62 per August 2025 Unit, raising gross proceeds of approximately C$0.8 million (the “August 2025 Offering“). Each August 2025 Unit consisted of (i) one common share in the capital of the Company (each, a “Common Share“), and (ii) one-half of one Common Share purchase warrant (each, an “August 2025 Warrant“). Each August 2025 Warrant entitles the holder thereof to purchase one Common Share at a price of C$0.80 per Common Share for a period of 36 months.
On September 11, 2025, the Company completed a non-brokered private placement of 930,376 units (each, a “September 2025 Unit“) at a price of C$0.68 per September 2025 Unit, raising gross proceeds of approximately C$0.6 million (the “September 2025 Offering“). Each September 2025 Unit consisted of (i) one Common Share, and (ii) one-half of one Common Share purchase warrant (each, a “September 2025 Warrant“). Each September 2025 Warrant entitles the holder thereof to purchase one Common Share at a price of C$0.88 per Common Share for a period of 36 months.
The proceeds from the August and September 2025 Offerings will be used primarily for working capital, and also to support general corporate purposes and clinical development activities.
Patents Grants in the U.S. and Israel Strengthen Intellectual Property and Manufacturing Position
NurExone strengthened its intellectual property and manufacturing foundation during Q3 2025 with a U.S. Notice of Allowance covering its proprietary exosome production process and a corresponding patent grant in Israel for the same priority family. These protections reinforce the Company’s long-term manufacturing strategy, building on the recent acquisition of a GMP-grade Master Cell Bank and supporting the development of a reliable, scalable supply chain for future clinical and commercial use.
On September 8, 2025, the Company received a Notice of Allowance from the U.S. Patent and Trademark Office for its proprietary exosome manufacturing process, covering its 3D scaffold and shear-stress–based bioreactor system. The patent was granted on …
Leave a Reply
You must be logged in to post a comment.